The Allogeneic Transplantation Service is part of the Parkville Integrated Haematology Service and is located at the VCCC in Parkville. Our service is the largest transplant service in Victoria and the second largest in Australia. In addition to providing allogeneic transplants to patients...
Biography
Professor Szer has particular expertise in malignant haematology and haemopoietic stem cell transplantation, which he established as a form of therapy in Vicotria in the early 1980s.. He is a recognised key opinion leader in the rare non-malignant disorders paroxysmal nocturnal haemoglobinuria and Gaucher disease. He is a member of the Medical and Scientific Advisory Group of Myeloma Australia and is President of the Worldwide Network for Blood and Marrow Transplantation. He has been Director of the Western ad Central Melbourne Integrated Cancer Service since 2009. He has also been Editor in Chief of Internal Medicine Jounral since 2005 and is ont he editorial board of several other international journals.
Related Links
Haematology
Allogeneic Transplantation
Myeloma and Autologous Stem Cell Transplantation
Non-Malignant Haematology
Awards
Member of the Order of Australia (2015). de Gruchy Oration and Medal, Haematology Sociaty of Australia and New Zealand (2012), Mortimer M Bortin Memorial Lecture, Centre for International Blood and Marrow Transplant Research (2014).
Qualifications
BMedSc MB BS FRACP
Publications
1. Hillmen P, Muus P, Röth A, Elebute MO, Risitano AM, Schrezenmeier H, Szer J, Browne P, Maciejewski JP, Schubert J, Urbano-Ispizua A, de Castro C, Socié G, Brodsky RA. Long-term safety and efficacy of sustained eculizumab treatment in patients with paroxysmal nocturnal haemoglobinuria. Br J Haematol. 2013;162:62-73
2. Aljurf M, Rizzo JD, Mohty M, Hussain F, Madrigal A, Pasquini MC, Passweg J, Chaudhri N, Ghavamzadeh A, El Solh H, Atsuta Y, Szer J, Kodera Y, Niederweiser D , Gratwohl A, Horowitz MM. Challenges and opportunities for outcomes registries; Perspectives from international HSCT Registries experts. Bone Marrow Transplant. 2014;49:1016-1021
3. Pastores GM, Petakov M, Giraldo P, Rosenbaum H, Szer J, Deegan PB, Amato DJ, Mengel E, Tan ES, Chertkoff R, Brill-Almon E, Zimran A. A Phase 3, multicenter, open-label, switchover trial to assess the safety and efficacy of taliglucerase alfa, a plant cell-expressed recombinant human glucocerebrosidase, in adult and pediatric patients with Gaucher disease previously treated with imiglucerase. Blood Cells Mol Dis. 2014;53:253-260
4. Kelly RJ, Höchsmann B, Szer J, Kulasekararaj A, de Guibert S, Röth A, Weitz IC, Armstrong E, Risitano AM, Patriquin CJ, Terriou L, Muus P, Hill A, Turner MP, Schrezenmeier H, Peffault de Latour R. Eculizumab in Pregnant Patients with Paroxysmal Nocturnal Hemoglobinuria. N Engl J Med 2015;373:1032-1039.
